{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T18:52:18Z","timestamp":1785351138082,"version":"3.55.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":514,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["A*STAR-NZ HRC:JGC 10_027"],"award-info":[{"award-number":["A*STAR-NZ HRC:JGC 10_027"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001516","name":"Heart Foundation of New Zealand","doi-asserted-by":"publisher","award":["1603 & 1743"],"award-info":[{"award-number":["1603 & 1743"]}],"id":[{"id":"10.13039\/501100001516","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Heart Foundation of New Zealand Chair of Heart Health"},{"name":"Heart Foundation of New Zealand Chair of Cardiovascular Studies"},{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["A*STAR\u2010NZ HRC:JGC 10_027"],"award-info":[{"award-number":["A*STAR\u2010NZ HRC:JGC 10_027"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001516","name":"National Heart Foundation of New Zealand","doi-asserted-by":"publisher","award":["1603 & 1743"],"award-info":[{"award-number":["1603 & 1743"]}],"id":[{"id":"10.13039\/501100001516","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF), components of the vascular endothelial growth factor (VEGF) system, play key roles in angiogenesis. Reports of elevated plasma levels of sFlt-1 and PlGF in coronary heart disease and heart failure (HF) led us to investigate their utility, and VEGF system gene single nucleotide polymorphisms (SNPs), as prognostic biomarkers in HF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>ELISA assays for sFlt-1, PlGF and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were performed on baseline plasma samples from the PEOPLE cohort (n\u2009=\u2009890), a study of outcomes among patients after an episode of acute decompensated HF. Eight SNPs potentially associated with sFlt-1 or PlGF levels were genotyped. sFlt-1 and PlGF were assayed in 201 subjects from the Canterbury Healthy Volunteers Study (CHVS) matched to PEOPLE participants. All-cause death was the major endpoint for clinical outcome considered. In PEOPLE participants, mean plasma levels for both sFlt-1 (125\u2009\u00b1\u20092.01\u2009pg\/ml) and PlGF (17.5\u2009\u00b1\u20090.21\u2009pg\/ml) were higher (both p\u2009&amp;lt;\u20090.044) than in the CHVS cohort (81.2\u2009\u00b1\u20091.31\u2009pg\/ml and 15.5\u2009\u00b1\u20090.32\u2009pg\/ml, respectively). sFlt-1 was higher in HF with reduced ejection fraction compared to HF with preserved ejection fraction (p\u2009=\u20090.005). The PGF gene SNP rs2268616 was univariately associated with death (p\u2009=\u20090.016), and was also associated with PlGF levels, as was rs2268614 genotype. Cox proportional hazards modelling (n\u2009=\u2009695, 246 deaths) showed plasma sFlt-1, but not PlGF, predicted survival (hazard ratio 6.44, 95% confidence interval 2.57\u201316.1; p\u2009&amp;lt;\u20090.001) in PEOPLE, independent of age, NT-proBNP, ischaemic aetiology, diabetic status and beta-blocker therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Plasma sFlt-1 concentrations have potential as an independent predictor of survival and may be complementary to established prognostic biomarkers in HF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.3368","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T15:08:35Z","timestamp":1720537715000},"page":"1804-1813","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Plasma Soluble Fms-Like Tyrosine Kinase-1, Placental Growth Factor, and Vascular Endothelial Growth Factor System Gene Variants as Predictors of Survival in Heart Failure"],"prefix":"10.1093","volume":"26","author":[{"given":"Melinda A.","family":"Paterson","sequence":"first","affiliation":[{"name":"Department of Medicine, Christchurch Heart Institute, University of Otago Christchurch , Christchurch ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna P.","family":"Pilbrow","sequence":"additional","affiliation":[{"name":"Department of Medicine, Christchurch Heart Institute, University of Otago Christchurch , Christchurch ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris M.","family":"Frampton","sequence":"additional","affiliation":[{"name":"Department of Medicine, Christchurch Heart Institute, University of Otago Christchurch , Christchurch ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky A.","family":"Cameron","sequence":"additional","affiliation":[{"name":"Department of Medicine, Christchurch Heart Institute, University of Otago Christchurch , Christchurch ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard W.","family":"Troughton","sequence":"additional","affiliation":[{"name":"Department of Medicine, Christchurch Heart Institute, University of Otago Christchurch , Christchurch ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris J.","family":"Pemberton","sequence":"additional","affiliation":[{"name":"Department of Medicine, Christchurch Heart Institute, University of Otago Christchurch , Christchurch ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayanna","family":"Lund","sequence":"additional","affiliation":[{"name":"Cardiology Department, Middlemore Hospital , Auckland ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard P.","family":"Devlin","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Waikato District Health Board , Hamilton ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Mark","family":"Richards","sequence":"additional","affiliation":[{"name":"Department of Medicine, Christchurch Heart Institute, University of Otago Christchurch , Christchurch ,","place":["New Zealand"]},{"name":"Cardiovascular Research Institute, National University of Singapore , Singapore ,","place":["Singapore"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert N.","family":"Doughty","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medicine and Health Sciences, University of Auckland , Auckland ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0741-5033","authenticated-orcid":false,"given":"Barry R.","family":"Palmer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Christchurch Heart Institute, University of Otago Christchurch , Christchurch ,","place":["New Zealand"]},{"name":"School of Health Sciences, College of Health, Massey University , Wellington ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"key":"2026010913054487800_ejhf3368-bib-0001","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.738325","article-title":"The role of the VEGF family in coronary heart disease","volume":"8","author":"Zhou","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2026010913054487800_ejhf3368-bib-0002","doi-asserted-by":"crossref","first-page":"10705","DOI":"10.1073\/pnas.90.22.10705","article-title":"Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor","volume":"90","author":"Kendall","year":"1993","journal-title":"Proc Natl Acad Sci U\u2009S\u2009A"},{"key":"2026010913054487800_ejhf3368-bib-0003","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.2169\/internalmedicine.52.9073","article-title":"An elevated ratio of placental growth factor to soluble fms-like tyrosine kinase-1 predicts adverse outcomes in patients with stable coronary artery disease","volume":"52","author":"Matsumoto","year":"2013","journal-title":"Intern Med"},{"key":"2026010913054487800_ejhf3368-bib-0004","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1161\/01.CIR.97.1.99","article-title":"Vascular endothelial growth factor\/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin","volume":"97","author":"Murohara","year":"1998","journal-title":"Circulation"},{"key":"2026010913054487800_ejhf3368-bib-0005","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ijcard.2007.10.050","article-title":"Elevation of plasma placental growth factor in the patients with ischemic cardiomyopathy","volume":"131","author":"Nakamura","year":"2009","journal-title":"Int J Cardiol"},{"key":"2026010913054487800_ejhf3368-bib-0006","doi-asserted-by":"crossref","first-page":"15","DOI":"10.21037\/amj.2020.03.03","article-title":"Global epidemiology and future trends of heart failure","volume":"5","author":"Lippi","year":"2020","journal-title":"AME Med J"},{"key":"2026010913054487800_ejhf3368-bib-0007","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ehf2.12005","article-title":"Heart failure: Preventing disease and death worldwide","volume":"1","author":"Ponikowski","year":"2014","journal-title":"ESC Heart Fail"},{"key":"2026010913054487800_ejhf3368-bib-0008","volume-title":"Annual Data Explorer 2020\/21: New Zealand Health Survey","author":"Ministry of Health New Zealand"},{"key":"2026010913054487800_ejhf3368-bib-0009","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/imj.15253","article-title":"Temporal trends in the burden of heart failure","volume":"51","author":"Chan","year":"2021","journal-title":"Intern Med J"},{"key":"2026010913054487800_ejhf3368-bib-0010","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.hfc.2014.04.006","article-title":"Natriuretic peptides in heart failure with preserved ejection fraction","volume":"10","author":"Richards","year":"2014","journal-title":"Heart Fail Clin"},{"key":"2026010913054487800_ejhf3368-bib-0011","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cardfail.2013.01.007","article-title":"The Singapore Heart Failure Outcomes and Phenotypes (SHOP) study and Prospective Evaluation of Outcome in Patients with Heart Failure with Preserved Left Ventricular Ejection Fraction (PEOPLE) study: Rationale and design","volume":"19","author":"Santhanakrishnan","year":"2013","journal-title":"J Card Fail"},{"key":"2026010913054487800_ejhf3368-bib-0012","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026010913054487800_ejhf3368-bib-0013","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13092534","article-title":"Endothelial dysfunction in heart failure: What is its role?","volume":"13","author":"Drera","year":"2024","journal-title":"J Clin Med"},{"key":"2026010913054487800_ejhf3368-bib-0014","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12872-018-0894-1","article-title":"Plasma levels of soluble VEGF receptor isoforms, circulating pterins and VEGF system SNPs as prognostic biomarkers in patients with acute coronary syndromes","volume":"18","author":"Marks","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"2026010913054487800_ejhf3368-bib-0015","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002115","article-title":"Elevated soluble Fms-like tyrosine kinase-1 and placental-like growth factor levels are associated with development and mortality risk in heart failure","volume":"9","author":"Hammadah","year":"2016","journal-title":"Circ Heart Fail"},{"key":"2026010913054487800_ejhf3368-bib-0016","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jacc.2011.03.032","article-title":"The vascular marker soluble fms-like tyrosine kinase 1 is associated with disease severity and adverse outcomes in chronic heart failure","volume":"58","author":"Ky","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026010913054487800_ejhf3368-bib-0017","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1093\/eurheartj\/ehy005","article-title":"Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study","volume":"39","author":"Lam","year":"2018","journal-title":"Eur Heart J"},{"key":"2026010913054487800_ejhf3368-bib-0018","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1161\/CIRCGENETICS.111.960336","article-title":"Genomic risk variants at 1p13.3, 1q41, and 3q22.3 are associated with subsequent cardiovascular outcomes in healthy controls and in established coronary artery disease","volume":"4","author":"Ellis","year":"2011","journal-title":"Circ Cardiovasc Genet"},{"key":"2026010913054487800_ejhf3368-bib-0019","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jacc.2018.11.060","article-title":"Combining circulating microRNA and NT-proBNP to detect and categorize heart failure subtypes","volume":"73","author":"Wong","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026010913054487800_ejhf3368-bib-0020","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1161\/CIRCULATIONAHA.113.006855","article-title":"Heart failure with recovered ejection fraction: Clinical description, biomarkers, and outcomes","volume":"129","author":"Basuray","year":"2014","journal-title":"Circulation"},{"key":"2026010913054487800_ejhf3368-bib-0021","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.cca.2019.10.029","article-title":"sST2 as a value-added biomarker in heart failure","volume":"501","author":"Lotierzo","year":"2020","journal-title":"Clin Chim Acta"},{"key":"2026010913054487800_ejhf3368-bib-0022","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/14017431.2019.1583363","article-title":"ST2 in heart failure with preserved and reduced ejection fraction","volume":"53","author":"Najjar","year":"2019","journal-title":"Scand Cardiovasc J"},{"key":"2026010913054487800_ejhf3368-bib-0023","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/00365513.2016.1190863","article-title":"Sflt-1 in heart failure: Relation with disease severity and biomarkers","volume":"76","author":"Gruson","year":"2016","journal-title":"Scand J Clin Lab Invest"},{"key":"2026010913054487800_ejhf3368-bib-0024","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1159\/000367807","article-title":"Flk-1\/KDR mediates ethanol-stimulated endothelial cell notch signaling and angiogenic activity","volume":"51","author":"Morrow","year":"2014","journal-title":"J Vasc Res"},{"key":"2026010913054487800_ejhf3368-bib-0025","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1360-0443.2010.02899.x","article-title":"The relation between different dimensions of alcohol consumption and burden of disease: An overview","volume":"105","author":"Rehm","year":"2010","journal-title":"Addiction"},{"key":"2026010913054487800_ejhf3368-bib-0026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042537","article-title":"Genetic and environmental factors influencing the placental growth factor (PGF) variation in two populations","volume":"7","author":"Sorice","year":"2012","journal-title":"PLoS One"},{"key":"2026010913054487800_ejhf3368-bib-0027","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/ced.14102","article-title":"Genetic interaction between placental growth factor and vascular endothelial growth factor a in psoriasis","volume":"45","author":"Young","year":"2020","journal-title":"Clin Exp Dermatol"},{"key":"2026010913054487800_ejhf3368-bib-0028","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nrcardio.2013.94","article-title":"Vascular endothelial growth factor in heart failure","volume":"10","author":"Taimeh","year":"2013","journal-title":"Nat Rev Cardiol"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/8\/1804\/65511855\/eurjhf_26_8_1804.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/8\/1804\/65511855\/eurjhf_26_8_1804.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:06:49Z","timestamp":1767982009000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/26\/8\/1804\/8328706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":28,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,7,9]]},"published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3368","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,7,9]]},"assertion":[{"value":"2024-03-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}